| Category | Patented Medicine Prices Review Board | Prescrire International† |
|---|---|---|
| Major therapeutic gain | Breakthrough Substantial improvement | Bravo A real advance |
| Moderate therapeutic gain | Moderate (primary or secondary) | Offers an advantage |
| Little to no therapeutic gain | Slight or no improvement | Possibly helpful Nothing new Not acceptable |
*Ratings from the 2 organizations were grouped to make them comparable in terms of their assessment of the new therapeutic value offered.
†The Prescrire category "judgment reserved" was not used.